192 related articles for article (PubMed ID: 1701343)
1. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
[TBL] [Abstract][Full Text] [Related]
2. Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients.
Brugger W; Scheibenbogen C; Krause S; Andreesen R
Cancer Detect Prev; 1991; 15(5):407-12. PubMed ID: 1751952
[TBL] [Abstract][Full Text] [Related]
3. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
[TBL] [Abstract][Full Text] [Related]
4. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
6. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
7. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3.
Chokri M; Lopez M; Oleron C; Girard A; Martinache C; Canepa S; Siffert JC; Bartholeyns J
Anticancer Res; 1992; 12(6B):2257-60. PubMed ID: 1295473
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes.
Hennemann B; Rehm A; Kottke A; Meidenbauer N; Andreesen R
J Immunother; 1997 Sep; 20(5):365-71. PubMed ID: 9336743
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with autologous macrophages: current status and future perspectives.
Andreesen R; Hennemann B
Pathobiology; 1991; 59(4):259-63. PubMed ID: 1883523
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
12. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.
Hahn G; Stuhlmüller B; Hain N; Kalden JR; Pfizenmaier K; Burmester GR
J Clin Invest; 1993 Mar; 91(3):862-70. PubMed ID: 8450066
[TBL] [Abstract][Full Text] [Related]
13. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages.
Thomassen MJ; Barna BP; Rankin D; Wiedemann HP; Ahmad M
Cancer Res; 1989 Aug; 49(15):4086-9. PubMed ID: 2545332
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of inhibitory macrophage differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor and interferon-gamma from lineage phenotypes-negative c-kit-positive murine hematopoietic progenitor cells.
Ferret-Bernard S; Saï P; Bach JM
Immunol Lett; 2004 Feb; 91(2-3):221-7. PubMed ID: 15019293
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration.
Kleinerman ES; Knowles RD; Lachman LB; Gutterman JU
Cancer Res; 1988 May; 48(9):2604-9. PubMed ID: 3128401
[TBL] [Abstract][Full Text] [Related]
19. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
